Review



sybr green nucleic acid gel stain tsingke biotech n a one step tunel apoptosis assay kit beyotime c1086 dapi  (Beyotime)


Bioz Verified Symbol Beyotime is a verified supplier
Bioz Manufacturer Symbol Beyotime manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 98

    Structured Review

    Beyotime sybr green nucleic acid gel stain tsingke biotech n a one step tunel apoptosis assay kit beyotime c1086 dapi
    Sybr Green Nucleic Acid Gel Stain Tsingke Biotech N A One Step Tunel Apoptosis Assay Kit Beyotime C1086 Dapi, supplied by Beyotime, used in various techniques. Bioz Stars score: 98/100, based on 3818 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+dapi/One+Step+TUNEL+Apoptosis+Assay+Kit/pm42827202-200-167-182
    Average 98 stars, based on 3818 article reviews
    sybr green nucleic acid gel stain tsingke biotech n a one step tunel apoptosis assay kit beyotime c1086 dapi - by Bioz Stars, 2026-10
    98/100 stars

    Images

    Related Articles

    Staining:

    Article Title: Transketolase-like 1 potentiates PD-1 blockade in hepatocellular carcinoma by glycolysis to prime dendritic cell lactylation.
    Article Snippet: The treated samples were then linked with either Alexa Fluorite or HRP (Beyotime, China) at room temperature. .. A combined secondary antibody was applied and left to incubate for 1 h. To maintain the integrity of the nucleus, DAPI staining (Beyotime, China) was utilized. .. Subsequent to drying, images were captured utilizing a laser scanning confocal microscope from Zeiss, Germany.

    Article Title: IL-23-engineered oncolytic vaccinia virus enhances pancreatic cancer control through inflammasome-driven Th17-skewed CD4 + T-cell responses.
    Article Snippet: The secondary antibody solution was prepared in blocking buffer and used at a 1:1000 dilution of goat anti- rabbit Alexa Fluor Plus 488 (Thermo Scientific, no. A32731). .. After three washes with DPBS, the cells were stained with DAPI (Beyotime, no. C1002) for 5 min, and coverslips were mounted with Fluorescence Mounting Medium (Dako, no. S3023) on glass slides. .. Images were acquired using a Yokogawa Spinning Disk Field Scanning Confocal System (Nikon, CSU- W1).

    Article Title: Transketolase-like 1 potentiates PD-1 blockade in hepatocellular carcinoma by glycolysis to prime dendritic cell lactylation
    Article Snippet: The treated samples were then linked with either Alexa Fluorite or HRP (Beyotime, China) at room temperature. .. A combined secondary antibody was applied and left to incubate for 1 h. To maintain the integrity of the nucleus, DAPI staining (Beyotime, China) was utilized. .. Subsequent to drying, images were captured utilizing a laser scanning confocal microscope from Zeiss, Germany.

    Article Title: Revitalizing bioinert PCL: A biomimetic 3D-Printed gradient-pore scaffold with CSMA hydrogel-mediated BMP-2/QK delivery for vascularized bone regeneration.
    Article Snippet: Critical-sized bone defects exceed bone’s regenerative capacity and require space-maintaining implants that support vascular and bone-tissue ingrowth.. Three-dimensional (3D)-printed polycaprolactone (PCL) scaffolds are widely investigated for bone repair owing to controllable geometry, interconnected macropores, and structural stability.. However, uniform-pore designs cannot recapitulate heterogeneous bone porosity, while hydrophobic PCL has limited bioactivity.

    Article Title: The response mechanism of mandarin fish (Siniperca chuatsi) astrocyte-like cells to SCRV infection: Insights from Transcriptome Sequencing.
    Article Snippet: A novel cell line, designated SCAC01 (Siniperca chuatsi Astrocyte clone 01), was established from the brain of mandarin fish (S. chuatsi).. SCAC01 cell line highly expressed the astrocyte-specific marker gfap and could be stably passaged for more than 60 generations.. The cell line exhibited high susceptibility to S. chuatsi rhabdovirus (SCRV) and supported robust viral replication accompanied by obviously cytopathic effects.

    Article Title: Cross-species TNF-α signaling in mosquitoes promotes malaria transmission.
    Article Snippet: After thorough washing, samples were subsequently incubated for 2 h at room temperature under lightprotected conditions with species-matched secondary antibodies: Alexa Fluor 488-conjugated goat anti-rabbit IgG (Beyotime Biotech, A0423), with or without Alexa Fluor 647-conjugated goat anti-mouse IgG (Beyotime Biotech, A0473), both diluted 1:500 in PBS. .. Nuclei were stained with 1 μg/mL DAPI (Beyotime Biotech, C1002) for 10 min. For actin visualization, midguts were incubated with 1 U phalloidin (Invitrogen, A2284) for 30 min. .. Samples were mounted using Dako Fluorescence Mounting Medium (S3023, Agilent) and stored at 4 °C in darkness.

    Article Title: Notoginsenoside R1 modulates the ATF4-CHOP-Bcl2 signaling pathway to alleviate mitochondrial stress damage and apoptosis in asthmatic airway epithelial cells
    Article Snippet: Subsequently, the sections were covered with the TUNEL detection solution (MeilunBio, Dalian, China, MA0224) and incubated in the dark. .. Following this, DAPI staining (Beyotime, Shanghai, China, C1006) was performed. .. Immediately after staining, the sections were mounted with antifade mounting medium (Beyotime, Shanghai, China, P0131) and imaged using a laser confocal microscope (Nikon, Tokyo, Japan).

    Fluorescence:

    Article Title: IL-23-engineered oncolytic vaccinia virus enhances pancreatic cancer control through inflammasome-driven Th17-skewed CD4 + T-cell responses.
    Article Snippet: The secondary antibody solution was prepared in blocking buffer and used at a 1:1000 dilution of goat anti- rabbit Alexa Fluor Plus 488 (Thermo Scientific, no. A32731). .. After three washes with DPBS, the cells were stained with DAPI (Beyotime, no. C1002) for 5 min, and coverslips were mounted with Fluorescence Mounting Medium (Dako, no. S3023) on glass slides. .. Images were acquired using a Yokogawa Spinning Disk Field Scanning Confocal System (Nikon, CSU- W1).

    Article Title: The response mechanism of mandarin fish (Siniperca chuatsi) astrocyte-like cells to SCRV infection: Insights from Transcriptome Sequencing.
    Article Snippet: A novel cell line, designated SCAC01 (Siniperca chuatsi Astrocyte clone 01), was established from the brain of mandarin fish (S. chuatsi).. SCAC01 cell line highly expressed the astrocyte-specific marker gfap and could be stably passaged for more than 60 generations.. The cell line exhibited high susceptibility to S. chuatsi rhabdovirus (SCRV) and supported robust viral replication accompanied by obviously cytopathic effects.

    Glass:

    Article Title: IL-23-engineered oncolytic vaccinia virus enhances pancreatic cancer control through inflammasome-driven Th17-skewed CD4 + T-cell responses.
    Article Snippet: The secondary antibody solution was prepared in blocking buffer and used at a 1:1000 dilution of goat anti- rabbit Alexa Fluor Plus 488 (Thermo Scientific, no. A32731). .. After three washes with DPBS, the cells were stained with DAPI (Beyotime, no. C1002) for 5 min, and coverslips were mounted with Fluorescence Mounting Medium (Dako, no. S3023) on glass slides. .. Images were acquired using a Yokogawa Spinning Disk Field Scanning Confocal System (Nikon, CSU- W1).

    Saline:

    Article Title: Revitalizing bioinert PCL: A biomimetic 3D-Printed gradient-pore scaffold with CSMA hydrogel-mediated BMP-2/QK delivery for vascularized bone regeneration.
    Article Snippet: Critical-sized bone defects exceed bone’s regenerative capacity and require space-maintaining implants that support vascular and bone-tissue ingrowth.. Three-dimensional (3D)-printed polycaprolactone (PCL) scaffolds are widely investigated for bone repair owing to controllable geometry, interconnected macropores, and structural stability.. However, uniform-pore designs cannot recapitulate heterogeneous bone porosity, while hydrophobic PCL has limited bioactivity.

    Microscopy:

    Article Title: The response mechanism of mandarin fish (Siniperca chuatsi) astrocyte-like cells to SCRV infection: Insights from Transcriptome Sequencing.
    Article Snippet: A novel cell line, designated SCAC01 (Siniperca chuatsi Astrocyte clone 01), was established from the brain of mandarin fish (S. chuatsi).. SCAC01 cell line highly expressed the astrocyte-specific marker gfap and could be stably passaged for more than 60 generations.. The cell line exhibited high susceptibility to S. chuatsi rhabdovirus (SCRV) and supported robust viral replication accompanied by obviously cytopathic effects.

    Incubation:

    Article Title: Cross-species TNF-α signaling in mosquitoes promotes malaria transmission.
    Article Snippet: After thorough washing, samples were subsequently incubated for 2 h at room temperature under lightprotected conditions with species-matched secondary antibodies: Alexa Fluor 488-conjugated goat anti-rabbit IgG (Beyotime Biotech, A0423), with or without Alexa Fluor 647-conjugated goat anti-mouse IgG (Beyotime Biotech, A0473), both diluted 1:500 in PBS. .. Nuclei were stained with 1 μg/mL DAPI (Beyotime Biotech, C1002) for 10 min. For actin visualization, midguts were incubated with 1 U phalloidin (Invitrogen, A2284) for 30 min. .. Samples were mounted using Dako Fluorescence Mounting Medium (S3023, Agilent) and stored at 4 °C in darkness.

    other:

    Article Title: A dual-action bacteriophage protein Ped1 degrades DNA and blocks replication in Pseudomonas aeruginosa.
    Article Snippet: Reagents and tools table Reagent/resource Reference or source Identifier or catalog number Experimental models List of P. aeruginosa and E. coli strains This paper Dataset EV5 List of Pseudomonas aeruginosa phage PaoP5 This paper Dataset EV5 Recombinant DNA List of plasmids This paper Dataset EV5 Antibodies Mouse anti DDDDK-Tag mAb Abclonal AE005 Mouse anti-His-Tag mAb Abclonal AE003 Mouse anti-GST-Tag mAb Abclonal AE001 HRP-conjugated Goat antiMouse IgG (H+ L) Abclonal AS003 Purified anti-E. coli RNA Polymerase α Antibody BioLegend 663104 Oligonucleotides and other sequence-based reagents oligonucleotide sequence information This paper Dataset EV6 Chemicals, enzymes, and other reagents IPTG (Isopropyl β-D-1thiogalactopyranoside) SigmaAldrich I6758 L-Arabinose SigmaAldrich A3256 Carbenicillin SigmaAldrich C1389 Gentamicin SigmaAldrich G1397 Tetracycline SigmaAldrich T7660 Kanamycin SigmaAldrich K4000 DNase I TransGen Biotech GD201-01 DNase I reaction buffer TransGen Biotech GD201-01 HiTrap Desalting column Cytiva 17546508 HisTrap HP column Cytiva 11000458 GSTrap HP column Cytiva 28401747 Superdex 200 Increase 10/ 300 GL column Cytiva 17546508 10 The EMBO Journal © The Author(s) Reagent/resource Reference or source Identifier or catalog number SYBR Green nucleic acid gel stain Tsingke Biotech N/A One Step TUNEL Apoptosis Assay Kit Beyotime C1086 DAPI (4′,6-diamidino-2phenylindole) SigmaAldrich D9542 PURExpress In Vitro Protein Synthesis Kit New England Biolabs E6800S Murine RNase Inhibitor New England Biolabs M0314 SYBR Green PCR Master Mix abm G891 2×Es Taq MasterMix (Dye) cwbio CW0690S (1 ml) PrimeSTAR Max DNA Polymerase TaKaRa R045Q RNAprep Pure Cell/Bacteria Kit TianGen biotech DP430 Reverse transcriptase kit abm G592 SteadyPure Bacterial Genomic DNA Extraction Kit Accurate Biology AG21007 ECL Plus Kit Cytiva RPN418-1 PVDF membrane Millipore IPVH00010 X-gal (5-Bromo-4-chloro-3indolyl β-Dgalactopyranoside) SigmaAldrich B4252 ONPG (o-Nitrophenyl β-Dgalactopyranoside) SigmaAldrich N1127 QuickMutation Random Mutagenesis Kit Beyotime D0219S PreScission Protease Cytiva 27084301 anti-Flag M2 magnetic beads Sigma M8823 BiodyneTM B Nylon membrane Thermo Scientific 77016 Silver Staining Kit Beyotime P0017S Glutathione beads Beyotime P2258 Software Fiji ImageJ NIH https://imagej.net/ GraphPad Prism GraphPad Software Version 8.0 or later MEGA 7 MEGA software https://www.megasoftware.



    Similar Products

    97
    Miltenyi Biotec dapi
    Dapi, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+dapi/DAPI+Staining+Solution/pm42811304-68-17-18
    Average 97 stars, based on 1 article reviews
    dapi - by Bioz Stars, 2026-10
    97/100 stars
      Buy from Supplier

    98
    Beyotime sybr green nucleic acid gel stain tsingke biotech n a one step tunel apoptosis assay kit beyotime c1086 dapi
    Sybr Green Nucleic Acid Gel Stain Tsingke Biotech N A One Step Tunel Apoptosis Assay Kit Beyotime C1086 Dapi, supplied by Beyotime, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+dapi/One+Step+TUNEL+Apoptosis+Assay+Kit/pm42827202-200-167-182
    Average 98 stars, based on 1 article reviews
    sybr green nucleic acid gel stain tsingke biotech n a one step tunel apoptosis assay kit beyotime c1086 dapi - by Bioz Stars, 2026-10
    98/100 stars
      Buy from Supplier

    96
    Vector Laboratories dapi staining
    Confocal immunofluorescence images of S2-013 and HPNE cells that took up SNORA22 siRNA conjugated with FA-Dab8α and FA-Dab8γ. A S2-013 cells were incubated with Alexa Fluor 647-labeled chemically modified SNORA22 siRNA-FA-Dab8α and SNORA22 siRNA-FA-Dab8γ (green). Blue, <t>DAPI</t> staining. Scale bars, 10 µm. B Quantification of Alexa Fluor 647-labeled chemically modified SNORA22 siRNA-positive cells in A. Data represent the number of cells positive for the siRNA, scored across five fields per group and derived from two independent experiments. Columns , mean; bars , SD. * p <0.05 significantly different from SNORA22 siRNA-FA-Dab8γ (the Student’s t -test). C S2-013, S2-CP8, and HPNE cells were incubated with Alexa Fluor 647-labeled chemically modified SNORA22 siRNA-FA-Dab8α (green). Cells were stained with <t>an</t> <t>anti-FOLR1</t> antibody (red). Blue, DAPI staining. Scale bars, 10 µm. D Quantification of Alexa Fluor 647-labeled chemically modified SNORA22 siRNA-positive cells in C. Data represent the number of cells positive for the siRNA, scored across five fields per group and derived from two independent experiments. Columns , mean; bars , SD. * p <0.05 significantly different from HPNE cells (the Student’s t -test)
    Dapi Staining, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+dapi/VECTASHIELD+Hardset+Antifade+Mounting+Medium+with+DAPI/pmc13627270-85-48-55
    Average 96 stars, based on 1 article reviews
    dapi staining - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    99
    Beyotime dapi staining
    TKTL1 drives tumor progression while potentiating anti-PD-1 immunotherapy sensitivity rather than apatinib in HCC. a Schematic of the orthotopic tumor mouse model: Hepa1-6 cells transduced with OE-TKTL1 (TKTL1 overexpression) or OE-VE (vector control) lentiviruses were subcutaneously implanted, followed by tumor transplantation to the liver. Anti-PD-1 treatment was administered, with live imaging at day 21 and sample harvest at day 42. b Tumor growth curves of orthotopic models in OE-VE, OE-TKTL1, OE-VE+Anti-PD-1, and OE-TKTL1+Anti-PD-1 groups (days 21, 28, 35). c Quantification of tumor volume and tumor weight in each treatment group. Data are mean ± SD ( n = 5, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). d TUNEL <t>immunofluorescence</t> <t>staining</t> of orthotopic tumors to detect apoptotic cells. Scale bar: 50 µm. e Ki67 immunofluorescence staining of orthotopic tumors to assess cell proliferation. Scale bar: 50 µm. f Quantification of TUNEL-positive cells in orthotopic tumors. Data are mean ± SD ( n = 3, *** p < 0.001, **** p < 0.0001; One-way ANOVA). g Quantification of Ki67-positive cells in orthotopic tumors. Data are mean ± SD ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). h Immunofluorescence staining and analysis of CD8 + (green) and PD-1 + (red) T cells in orthotopic tumors. Nuclei: <t>DAPI</t> (blue). Scale bar: 50 µm. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). i Flow cytometry analysis of CD8 + T cell exhaustion markers (PD-1, CTLA-4, TOX) and effector cytokine (IFN-γ) in orthotopic tumor tissues. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). j Schematic of the diethylnitrosamine (DEN)/carbon tetrachloride (CCl4)-induced orthotopic HCC model: Mice were treated with DEN+CCl4, followed by AAV-VE (vector control) or AAV-TKTL1 injection at week 20, anti-PD-1 treatment from week 24, MRI scanning, and liver tissue harvest at week 28. k Representative micro-MRI images of mouse livers pre- and post-treatment; representative photographs of excised livers. Scale bar: 1 cm. H&E staining of tumor (T) and peritumoral (P) tissues from DEN/CCl4-induced models. Scale bar: 50 µm. l TUNEL and Ki67 immunofluorescence staining of DEN/CCl4-induced tumor tissues. Scale bar: 50 µm. m Quantification of tumor size changes pre- and post-treatment in DEN/CCl4-induced models related to ( k ). Data are mean ± SD ( n = 5, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). n Quantification of TUNEL-positive and Ki67-positive cells in DEN/CCl4-induced models related to ( l ). Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, *** p < 0.001, **** p < 0.0001; One-way ANOVA). o Immunofluorescence staining of CD8 + and PD-1 + CD8 + T cells in DEN/CCl4-induced tumors. Scale bar: 50 µm. p Quantification of CD8 + and PD-1 + CD8 + T cell proportions in DEN/CCl4-induced tumors. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001; One-way ANOVA). q Flow cytometry analysis of CD8 + T cell exhaustion markers (PD-1, CTLA-4, TOX) and effector cytokine (IFN-γ) in DEN/CCl4-induced tumor tissues. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). r Schematic illustrating the role of TKTL1 in promoting HCC progression and sensitizing tumors to anti-PD-1 immunotherapy via modulating CD8 + T cell function in the TME
    Dapi Staining, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+dapi/DAPI/pmc13616917-395-20-22
    Average 99 stars, based on 1 article reviews
    dapi staining - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    94
    Lumiprobe dapi
    TKTL1 drives tumor progression while potentiating anti-PD-1 immunotherapy sensitivity rather than apatinib in HCC. a Schematic of the orthotopic tumor mouse model: Hepa1-6 cells transduced with OE-TKTL1 (TKTL1 overexpression) or OE-VE (vector control) lentiviruses were subcutaneously implanted, followed by tumor transplantation to the liver. Anti-PD-1 treatment was administered, with live imaging at day 21 and sample harvest at day 42. b Tumor growth curves of orthotopic models in OE-VE, OE-TKTL1, OE-VE+Anti-PD-1, and OE-TKTL1+Anti-PD-1 groups (days 21, 28, 35). c Quantification of tumor volume and tumor weight in each treatment group. Data are mean ± SD ( n = 5, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). d TUNEL <t>immunofluorescence</t> <t>staining</t> of orthotopic tumors to detect apoptotic cells. Scale bar: 50 µm. e Ki67 immunofluorescence staining of orthotopic tumors to assess cell proliferation. Scale bar: 50 µm. f Quantification of TUNEL-positive cells in orthotopic tumors. Data are mean ± SD ( n = 3, *** p < 0.001, **** p < 0.0001; One-way ANOVA). g Quantification of Ki67-positive cells in orthotopic tumors. Data are mean ± SD ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). h Immunofluorescence staining and analysis of CD8 + (green) and PD-1 + (red) T cells in orthotopic tumors. Nuclei: <t>DAPI</t> (blue). Scale bar: 50 µm. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). i Flow cytometry analysis of CD8 + T cell exhaustion markers (PD-1, CTLA-4, TOX) and effector cytokine (IFN-γ) in orthotopic tumor tissues. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). j Schematic of the diethylnitrosamine (DEN)/carbon tetrachloride (CCl4)-induced orthotopic HCC model: Mice were treated with DEN+CCl4, followed by AAV-VE (vector control) or AAV-TKTL1 injection at week 20, anti-PD-1 treatment from week 24, MRI scanning, and liver tissue harvest at week 28. k Representative micro-MRI images of mouse livers pre- and post-treatment; representative photographs of excised livers. Scale bar: 1 cm. H&E staining of tumor (T) and peritumoral (P) tissues from DEN/CCl4-induced models. Scale bar: 50 µm. l TUNEL and Ki67 immunofluorescence staining of DEN/CCl4-induced tumor tissues. Scale bar: 50 µm. m Quantification of tumor size changes pre- and post-treatment in DEN/CCl4-induced models related to ( k ). Data are mean ± SD ( n = 5, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). n Quantification of TUNEL-positive and Ki67-positive cells in DEN/CCl4-induced models related to ( l ). Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, *** p < 0.001, **** p < 0.0001; One-way ANOVA). o Immunofluorescence staining of CD8 + and PD-1 + CD8 + T cells in DEN/CCl4-induced tumors. Scale bar: 50 µm. p Quantification of CD8 + and PD-1 + CD8 + T cell proportions in DEN/CCl4-induced tumors. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001; One-way ANOVA). q Flow cytometry analysis of CD8 + T cell exhaustion markers (PD-1, CTLA-4, TOX) and effector cytokine (IFN-γ) in DEN/CCl4-induced tumor tissues. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). r Schematic illustrating the role of TKTL1 in promoting HCC progression and sensitizing tumors to anti-PD-1 immunotherapy via modulating CD8 + T cell function in the TME
    Dapi, supplied by Lumiprobe, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+dapi/LumiNuc+DAPI%2C+blue+fluorescent+nucleic+acid+stain/pm42804097-66-15-16
    Average 94 stars, based on 1 article reviews
    dapi - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    99
    Beyotime dapi stains
    TKTL1 drives tumor progression while potentiating anti-PD-1 immunotherapy sensitivity rather than apatinib in HCC. a Schematic of the orthotopic tumor mouse model: Hepa1-6 cells transduced with OE-TKTL1 (TKTL1 overexpression) or OE-VE (vector control) lentiviruses were subcutaneously implanted, followed by tumor transplantation to the liver. Anti-PD-1 treatment was administered, with live imaging at day 21 and sample harvest at day 42. b Tumor growth curves of orthotopic models in OE-VE, OE-TKTL1, OE-VE+Anti-PD-1, and OE-TKTL1+Anti-PD-1 groups (days 21, 28, 35). c Quantification of tumor volume and tumor weight in each treatment group. Data are mean ± SD ( n = 5, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). d TUNEL <t>immunofluorescence</t> <t>staining</t> of orthotopic tumors to detect apoptotic cells. Scale bar: 50 µm. e Ki67 immunofluorescence staining of orthotopic tumors to assess cell proliferation. Scale bar: 50 µm. f Quantification of TUNEL-positive cells in orthotopic tumors. Data are mean ± SD ( n = 3, *** p < 0.001, **** p < 0.0001; One-way ANOVA). g Quantification of Ki67-positive cells in orthotopic tumors. Data are mean ± SD ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). h Immunofluorescence staining and analysis of CD8 + (green) and PD-1 + (red) T cells in orthotopic tumors. Nuclei: <t>DAPI</t> (blue). Scale bar: 50 µm. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). i Flow cytometry analysis of CD8 + T cell exhaustion markers (PD-1, CTLA-4, TOX) and effector cytokine (IFN-γ) in orthotopic tumor tissues. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). j Schematic of the diethylnitrosamine (DEN)/carbon tetrachloride (CCl4)-induced orthotopic HCC model: Mice were treated with DEN+CCl4, followed by AAV-VE (vector control) or AAV-TKTL1 injection at week 20, anti-PD-1 treatment from week 24, MRI scanning, and liver tissue harvest at week 28. k Representative micro-MRI images of mouse livers pre- and post-treatment; representative photographs of excised livers. Scale bar: 1 cm. H&E staining of tumor (T) and peritumoral (P) tissues from DEN/CCl4-induced models. Scale bar: 50 µm. l TUNEL and Ki67 immunofluorescence staining of DEN/CCl4-induced tumor tissues. Scale bar: 50 µm. m Quantification of tumor size changes pre- and post-treatment in DEN/CCl4-induced models related to ( k ). Data are mean ± SD ( n = 5, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). n Quantification of TUNEL-positive and Ki67-positive cells in DEN/CCl4-induced models related to ( l ). Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, *** p < 0.001, **** p < 0.0001; One-way ANOVA). o Immunofluorescence staining of CD8 + and PD-1 + CD8 + T cells in DEN/CCl4-induced tumors. Scale bar: 50 µm. p Quantification of CD8 + and PD-1 + CD8 + T cell proportions in DEN/CCl4-induced tumors. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001; One-way ANOVA). q Flow cytometry analysis of CD8 + T cell exhaustion markers (PD-1, CTLA-4, TOX) and effector cytokine (IFN-γ) in DEN/CCl4-induced tumor tissues. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). r Schematic illustrating the role of TKTL1 in promoting HCC progression and sensitizing tumors to anti-PD-1 immunotherapy via modulating CD8 + T cell function in the TME
    Dapi Stains, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+dapi/DAPI/pm42794663-139-0-5
    Average 99 stars, based on 1 article reviews
    dapi stains - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    99
    Beyotime nuclear staining with dapi
    TKTL1 drives tumor progression while potentiating anti-PD-1 immunotherapy sensitivity rather than apatinib in HCC. a Schematic of the orthotopic tumor mouse model: Hepa1-6 cells transduced with OE-TKTL1 (TKTL1 overexpression) or OE-VE (vector control) lentiviruses were subcutaneously implanted, followed by tumor transplantation to the liver. Anti-PD-1 treatment was administered, with live imaging at day 21 and sample harvest at day 42. b Tumor growth curves of orthotopic models in OE-VE, OE-TKTL1, OE-VE+Anti-PD-1, and OE-TKTL1+Anti-PD-1 groups (days 21, 28, 35). c Quantification of tumor volume and tumor weight in each treatment group. Data are mean ± SD ( n = 5, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). d TUNEL <t>immunofluorescence</t> <t>staining</t> of orthotopic tumors to detect apoptotic cells. Scale bar: 50 µm. e Ki67 immunofluorescence staining of orthotopic tumors to assess cell proliferation. Scale bar: 50 µm. f Quantification of TUNEL-positive cells in orthotopic tumors. Data are mean ± SD ( n = 3, *** p < 0.001, **** p < 0.0001; One-way ANOVA). g Quantification of Ki67-positive cells in orthotopic tumors. Data are mean ± SD ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). h Immunofluorescence staining and analysis of CD8 + (green) and PD-1 + (red) T cells in orthotopic tumors. Nuclei: <t>DAPI</t> (blue). Scale bar: 50 µm. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). i Flow cytometry analysis of CD8 + T cell exhaustion markers (PD-1, CTLA-4, TOX) and effector cytokine (IFN-γ) in orthotopic tumor tissues. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). j Schematic of the diethylnitrosamine (DEN)/carbon tetrachloride (CCl4)-induced orthotopic HCC model: Mice were treated with DEN+CCl4, followed by AAV-VE (vector control) or AAV-TKTL1 injection at week 20, anti-PD-1 treatment from week 24, MRI scanning, and liver tissue harvest at week 28. k Representative micro-MRI images of mouse livers pre- and post-treatment; representative photographs of excised livers. Scale bar: 1 cm. H&E staining of tumor (T) and peritumoral (P) tissues from DEN/CCl4-induced models. Scale bar: 50 µm. l TUNEL and Ki67 immunofluorescence staining of DEN/CCl4-induced tumor tissues. Scale bar: 50 µm. m Quantification of tumor size changes pre- and post-treatment in DEN/CCl4-induced models related to ( k ). Data are mean ± SD ( n = 5, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). n Quantification of TUNEL-positive and Ki67-positive cells in DEN/CCl4-induced models related to ( l ). Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, *** p < 0.001, **** p < 0.0001; One-way ANOVA). o Immunofluorescence staining of CD8 + and PD-1 + CD8 + T cells in DEN/CCl4-induced tumors. Scale bar: 50 µm. p Quantification of CD8 + and PD-1 + CD8 + T cell proportions in DEN/CCl4-induced tumors. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001; One-way ANOVA). q Flow cytometry analysis of CD8 + T cell exhaustion markers (PD-1, CTLA-4, TOX) and effector cytokine (IFN-γ) in DEN/CCl4-induced tumor tissues. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). r Schematic illustrating the role of TKTL1 in promoting HCC progression and sensitizing tumors to anti-PD-1 immunotherapy via modulating CD8 + T cell function in the TME
    Nuclear Staining With Dapi, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+dapi/DAPI/pm42791620-89-34-39
    Average 99 stars, based on 1 article reviews
    nuclear staining with dapi - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    96
    Boster Bio dapi solution boster cat
    TKTL1 drives tumor progression while potentiating anti-PD-1 immunotherapy sensitivity rather than apatinib in HCC. a Schematic of the orthotopic tumor mouse model: Hepa1-6 cells transduced with OE-TKTL1 (TKTL1 overexpression) or OE-VE (vector control) lentiviruses were subcutaneously implanted, followed by tumor transplantation to the liver. Anti-PD-1 treatment was administered, with live imaging at day 21 and sample harvest at day 42. b Tumor growth curves of orthotopic models in OE-VE, OE-TKTL1, OE-VE+Anti-PD-1, and OE-TKTL1+Anti-PD-1 groups (days 21, 28, 35). c Quantification of tumor volume and tumor weight in each treatment group. Data are mean ± SD ( n = 5, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). d TUNEL <t>immunofluorescence</t> <t>staining</t> of orthotopic tumors to detect apoptotic cells. Scale bar: 50 µm. e Ki67 immunofluorescence staining of orthotopic tumors to assess cell proliferation. Scale bar: 50 µm. f Quantification of TUNEL-positive cells in orthotopic tumors. Data are mean ± SD ( n = 3, *** p < 0.001, **** p < 0.0001; One-way ANOVA). g Quantification of Ki67-positive cells in orthotopic tumors. Data are mean ± SD ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). h Immunofluorescence staining and analysis of CD8 + (green) and PD-1 + (red) T cells in orthotopic tumors. Nuclei: <t>DAPI</t> (blue). Scale bar: 50 µm. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). i Flow cytometry analysis of CD8 + T cell exhaustion markers (PD-1, CTLA-4, TOX) and effector cytokine (IFN-γ) in orthotopic tumor tissues. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). j Schematic of the diethylnitrosamine (DEN)/carbon tetrachloride (CCl4)-induced orthotopic HCC model: Mice were treated with DEN+CCl4, followed by AAV-VE (vector control) or AAV-TKTL1 injection at week 20, anti-PD-1 treatment from week 24, MRI scanning, and liver tissue harvest at week 28. k Representative micro-MRI images of mouse livers pre- and post-treatment; representative photographs of excised livers. Scale bar: 1 cm. H&E staining of tumor (T) and peritumoral (P) tissues from DEN/CCl4-induced models. Scale bar: 50 µm. l TUNEL and Ki67 immunofluorescence staining of DEN/CCl4-induced tumor tissues. Scale bar: 50 µm. m Quantification of tumor size changes pre- and post-treatment in DEN/CCl4-induced models related to ( k ). Data are mean ± SD ( n = 5, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). n Quantification of TUNEL-positive and Ki67-positive cells in DEN/CCl4-induced models related to ( l ). Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, *** p < 0.001, **** p < 0.0001; One-way ANOVA). o Immunofluorescence staining of CD8 + and PD-1 + CD8 + T cells in DEN/CCl4-induced tumors. Scale bar: 50 µm. p Quantification of CD8 + and PD-1 + CD8 + T cell proportions in DEN/CCl4-induced tumors. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001; One-way ANOVA). q Flow cytometry analysis of CD8 + T cell exhaustion markers (PD-1, CTLA-4, TOX) and effector cytokine (IFN-γ) in DEN/CCl4-induced tumor tissues. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). r Schematic illustrating the role of TKTL1 in promoting HCC progression and sensitizing tumors to anti-PD-1 immunotherapy via modulating CD8 + T cell function in the TME
    Dapi Solution Boster Cat, supplied by Boster Bio, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+dapi/DAPI+(4'%2C6-Diamidino-2-Phenylindole%2C+Dihydrochloride)+for+nucleic+acid+staining/pm42785307-191-71-73
    Average 96 stars, based on 1 article reviews
    dapi solution boster cat - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    Image Search Results


    Confocal immunofluorescence images of S2-013 and HPNE cells that took up SNORA22 siRNA conjugated with FA-Dab8α and FA-Dab8γ. A S2-013 cells were incubated with Alexa Fluor 647-labeled chemically modified SNORA22 siRNA-FA-Dab8α and SNORA22 siRNA-FA-Dab8γ (green). Blue, DAPI staining. Scale bars, 10 µm. B Quantification of Alexa Fluor 647-labeled chemically modified SNORA22 siRNA-positive cells in A. Data represent the number of cells positive for the siRNA, scored across five fields per group and derived from two independent experiments. Columns , mean; bars , SD. * p <0.05 significantly different from SNORA22 siRNA-FA-Dab8γ (the Student’s t -test). C S2-013, S2-CP8, and HPNE cells were incubated with Alexa Fluor 647-labeled chemically modified SNORA22 siRNA-FA-Dab8α (green). Cells were stained with an anti-FOLR1 antibody (red). Blue, DAPI staining. Scale bars, 10 µm. D Quantification of Alexa Fluor 647-labeled chemically modified SNORA22 siRNA-positive cells in C. Data represent the number of cells positive for the siRNA, scored across five fields per group and derived from two independent experiments. Columns , mean; bars , SD. * p <0.05 significantly different from HPNE cells (the Student’s t -test)

    Journal: Human Cell

    Article Title: Inhibition of pancreatic cancer growth by an siRNA targeting SNORA22 and a folic acid-conjugated cationic oligopeptide

    doi: 10.1007/s13577-026-01458-1

    Figure Lengend Snippet: Confocal immunofluorescence images of S2-013 and HPNE cells that took up SNORA22 siRNA conjugated with FA-Dab8α and FA-Dab8γ. A S2-013 cells were incubated with Alexa Fluor 647-labeled chemically modified SNORA22 siRNA-FA-Dab8α and SNORA22 siRNA-FA-Dab8γ (green). Blue, DAPI staining. Scale bars, 10 µm. B Quantification of Alexa Fluor 647-labeled chemically modified SNORA22 siRNA-positive cells in A. Data represent the number of cells positive for the siRNA, scored across five fields per group and derived from two independent experiments. Columns , mean; bars , SD. * p <0.05 significantly different from SNORA22 siRNA-FA-Dab8γ (the Student’s t -test). C S2-013, S2-CP8, and HPNE cells were incubated with Alexa Fluor 647-labeled chemically modified SNORA22 siRNA-FA-Dab8α (green). Cells were stained with an anti-FOLR1 antibody (red). Blue, DAPI staining. Scale bars, 10 µm. D Quantification of Alexa Fluor 647-labeled chemically modified SNORA22 siRNA-positive cells in C. Data represent the number of cells positive for the siRNA, scored across five fields per group and derived from two independent experiments. Columns , mean; bars , SD. * p <0.05 significantly different from HPNE cells (the Student’s t -test)

    Article Snippet: This solution was added to each well, followed by a 48-h incubation with the addition of 1 mL of fresh DMEM at 24 h. Cells were then fixed with 4% paraformaldehyde, followed by immunostaining using an anti-folate receptor 1 (FOLR1) antibody (MAB5646, R&D Systems, Minneapolis, MN, USA) and DAPI staining (HardSet Mounting Medium with DAPI, Vector Laboratories, Burlingame, CA, USA).

    Techniques: Confocal, Immunofluorescence, Incubation, Labeling, Modification, Staining, Derivative Assay

    Localization of SNORA22 siRNA-FA-Dab8α and SNORA22 siRNA-FA-Dab8γ within lysosomes of S2-013 cells. Confocal immunofluorescence images show S2-013 cells incubated with Alexa Fluor 647-labeled chemically modified SNORA22 siRNA-FA-Dab8α and SNORA22 siRNA-FA-Dab8γ (green) and stained for lysosomes (LysoTracker, red) and nuclei (DAPI, blue). Cells enclosed in white boxes are shown at higher magnification below each panel to clearly demonstrate the specific colocalization of the nucleic acid compounds within the lysosomal compartments. Scale bars, 10 µm

    Journal: Human Cell

    Article Title: Inhibition of pancreatic cancer growth by an siRNA targeting SNORA22 and a folic acid-conjugated cationic oligopeptide

    doi: 10.1007/s13577-026-01458-1

    Figure Lengend Snippet: Localization of SNORA22 siRNA-FA-Dab8α and SNORA22 siRNA-FA-Dab8γ within lysosomes of S2-013 cells. Confocal immunofluorescence images show S2-013 cells incubated with Alexa Fluor 647-labeled chemically modified SNORA22 siRNA-FA-Dab8α and SNORA22 siRNA-FA-Dab8γ (green) and stained for lysosomes (LysoTracker, red) and nuclei (DAPI, blue). Cells enclosed in white boxes are shown at higher magnification below each panel to clearly demonstrate the specific colocalization of the nucleic acid compounds within the lysosomal compartments. Scale bars, 10 µm

    Article Snippet: This solution was added to each well, followed by a 48-h incubation with the addition of 1 mL of fresh DMEM at 24 h. Cells were then fixed with 4% paraformaldehyde, followed by immunostaining using an anti-folate receptor 1 (FOLR1) antibody (MAB5646, R&D Systems, Minneapolis, MN, USA) and DAPI staining (HardSet Mounting Medium with DAPI, Vector Laboratories, Burlingame, CA, USA).

    Techniques: Confocal, Immunofluorescence, Incubation, Labeling, Modification, Staining

    TKTL1 drives tumor progression while potentiating anti-PD-1 immunotherapy sensitivity rather than apatinib in HCC. a Schematic of the orthotopic tumor mouse model: Hepa1-6 cells transduced with OE-TKTL1 (TKTL1 overexpression) or OE-VE (vector control) lentiviruses were subcutaneously implanted, followed by tumor transplantation to the liver. Anti-PD-1 treatment was administered, with live imaging at day 21 and sample harvest at day 42. b Tumor growth curves of orthotopic models in OE-VE, OE-TKTL1, OE-VE+Anti-PD-1, and OE-TKTL1+Anti-PD-1 groups (days 21, 28, 35). c Quantification of tumor volume and tumor weight in each treatment group. Data are mean ± SD ( n = 5, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). d TUNEL immunofluorescence staining of orthotopic tumors to detect apoptotic cells. Scale bar: 50 µm. e Ki67 immunofluorescence staining of orthotopic tumors to assess cell proliferation. Scale bar: 50 µm. f Quantification of TUNEL-positive cells in orthotopic tumors. Data are mean ± SD ( n = 3, *** p < 0.001, **** p < 0.0001; One-way ANOVA). g Quantification of Ki67-positive cells in orthotopic tumors. Data are mean ± SD ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). h Immunofluorescence staining and analysis of CD8 + (green) and PD-1 + (red) T cells in orthotopic tumors. Nuclei: DAPI (blue). Scale bar: 50 µm. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). i Flow cytometry analysis of CD8 + T cell exhaustion markers (PD-1, CTLA-4, TOX) and effector cytokine (IFN-γ) in orthotopic tumor tissues. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). j Schematic of the diethylnitrosamine (DEN)/carbon tetrachloride (CCl4)-induced orthotopic HCC model: Mice were treated with DEN+CCl4, followed by AAV-VE (vector control) or AAV-TKTL1 injection at week 20, anti-PD-1 treatment from week 24, MRI scanning, and liver tissue harvest at week 28. k Representative micro-MRI images of mouse livers pre- and post-treatment; representative photographs of excised livers. Scale bar: 1 cm. H&E staining of tumor (T) and peritumoral (P) tissues from DEN/CCl4-induced models. Scale bar: 50 µm. l TUNEL and Ki67 immunofluorescence staining of DEN/CCl4-induced tumor tissues. Scale bar: 50 µm. m Quantification of tumor size changes pre- and post-treatment in DEN/CCl4-induced models related to ( k ). Data are mean ± SD ( n = 5, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). n Quantification of TUNEL-positive and Ki67-positive cells in DEN/CCl4-induced models related to ( l ). Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, *** p < 0.001, **** p < 0.0001; One-way ANOVA). o Immunofluorescence staining of CD8 + and PD-1 + CD8 + T cells in DEN/CCl4-induced tumors. Scale bar: 50 µm. p Quantification of CD8 + and PD-1 + CD8 + T cell proportions in DEN/CCl4-induced tumors. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001; One-way ANOVA). q Flow cytometry analysis of CD8 + T cell exhaustion markers (PD-1, CTLA-4, TOX) and effector cytokine (IFN-γ) in DEN/CCl4-induced tumor tissues. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). r Schematic illustrating the role of TKTL1 in promoting HCC progression and sensitizing tumors to anti-PD-1 immunotherapy via modulating CD8 + T cell function in the TME

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Transketolase-like 1 potentiates PD-1 blockade in hepatocellular carcinoma by glycolysis to prime dendritic cell lactylation

    doi: 10.1038/s41392-026-02875-2

    Figure Lengend Snippet: TKTL1 drives tumor progression while potentiating anti-PD-1 immunotherapy sensitivity rather than apatinib in HCC. a Schematic of the orthotopic tumor mouse model: Hepa1-6 cells transduced with OE-TKTL1 (TKTL1 overexpression) or OE-VE (vector control) lentiviruses were subcutaneously implanted, followed by tumor transplantation to the liver. Anti-PD-1 treatment was administered, with live imaging at day 21 and sample harvest at day 42. b Tumor growth curves of orthotopic models in OE-VE, OE-TKTL1, OE-VE+Anti-PD-1, and OE-TKTL1+Anti-PD-1 groups (days 21, 28, 35). c Quantification of tumor volume and tumor weight in each treatment group. Data are mean ± SD ( n = 5, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). d TUNEL immunofluorescence staining of orthotopic tumors to detect apoptotic cells. Scale bar: 50 µm. e Ki67 immunofluorescence staining of orthotopic tumors to assess cell proliferation. Scale bar: 50 µm. f Quantification of TUNEL-positive cells in orthotopic tumors. Data are mean ± SD ( n = 3, *** p < 0.001, **** p < 0.0001; One-way ANOVA). g Quantification of Ki67-positive cells in orthotopic tumors. Data are mean ± SD ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). h Immunofluorescence staining and analysis of CD8 + (green) and PD-1 + (red) T cells in orthotopic tumors. Nuclei: DAPI (blue). Scale bar: 50 µm. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). i Flow cytometry analysis of CD8 + T cell exhaustion markers (PD-1, CTLA-4, TOX) and effector cytokine (IFN-γ) in orthotopic tumor tissues. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). j Schematic of the diethylnitrosamine (DEN)/carbon tetrachloride (CCl4)-induced orthotopic HCC model: Mice were treated with DEN+CCl4, followed by AAV-VE (vector control) or AAV-TKTL1 injection at week 20, anti-PD-1 treatment from week 24, MRI scanning, and liver tissue harvest at week 28. k Representative micro-MRI images of mouse livers pre- and post-treatment; representative photographs of excised livers. Scale bar: 1 cm. H&E staining of tumor (T) and peritumoral (P) tissues from DEN/CCl4-induced models. Scale bar: 50 µm. l TUNEL and Ki67 immunofluorescence staining of DEN/CCl4-induced tumor tissues. Scale bar: 50 µm. m Quantification of tumor size changes pre- and post-treatment in DEN/CCl4-induced models related to ( k ). Data are mean ± SD ( n = 5, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). n Quantification of TUNEL-positive and Ki67-positive cells in DEN/CCl4-induced models related to ( l ). Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, *** p < 0.001, **** p < 0.0001; One-way ANOVA). o Immunofluorescence staining of CD8 + and PD-1 + CD8 + T cells in DEN/CCl4-induced tumors. Scale bar: 50 µm. p Quantification of CD8 + and PD-1 + CD8 + T cell proportions in DEN/CCl4-induced tumors. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001; One-way ANOVA). q Flow cytometry analysis of CD8 + T cell exhaustion markers (PD-1, CTLA-4, TOX) and effector cytokine (IFN-γ) in DEN/CCl4-induced tumor tissues. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). r Schematic illustrating the role of TKTL1 in promoting HCC progression and sensitizing tumors to anti-PD-1 immunotherapy via modulating CD8 + T cell function in the TME

    Article Snippet: A combined secondary antibody was applied and left to incubate for 1 h. To maintain the integrity of the nucleus, DAPI staining (Beyotime, China) was utilized.

    Techniques: Sensitivity, Transduction, Over Expression, Plasmid Preparation, Control, Transplantation Assay, Imaging, TUNEL Assay, Immunofluorescence, Staining, Analysis, Flow Cytometry, Injection, Tissue, Micro-MRI, Cell Function Assay

    TKTL1 reprograms glucose metabolism through glycolysis instead of the PPP to stabilize the HIF-1α/HK2/PD-L1 axis and drive anti-PD-1 sensitivity in HCC. a mRNA expression of glycolysis-related genes (SLC2A1, HK2, HKDC1) in TKTL1-knockdown Hep-3B cells, determined by RNA sequencing. b KEGG pathway enrichment analysis of downregulated differentially expressed genes (DEGs) in TKTL1-knockdown Hep-3B cells, highlighting Glycolysis/Gluconeogenesis and HIF-1α signaling pathways. c Bubble plot of KEGG pathway enrichment for downregulated metabolites from non-targeted metabolomics of TKTL1-knockdown cells, focusing on central carbon metabolism. d Integrative analysis of downregulated DEGs (RNA sequencing) and metabolites (non-targeted metabolomics), visualized as a ranked plot showing enrichment in glycolytic pathways. e Western blot analysis of glycolytic enzymes (GLUT1, HK2, PKM2, ENO1, LDHA) and TKTL1 in HCC-LM3 and Hep-3B cells with TKTL1 knockdown or overexpression. β-actin serves as a loading control. f 13 C-labeled glucose metabolic flux tracing analysis, showing the relative abundance of metabolites in glycolysis, PPP and tricarboxylic acid (TCA) cycle in TKTL1-knockdown vs. negative control (NC) cells. g Extracellular acidification rate (ECAR) measurements (left) and lactic acid production (right) in HCC-LM3 and Hep-3B cells under TKTL1 knockdown or overexpression. Data are mean ± SD ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; Student’s t-test). h , i Western blot analysis of TKTL1, HIF-1α, HK2, and PD-L1 protein expression in HCC-LM3 and Hep-3B cells with TKTL1 knockdown or overexpression. β-actin serves as a loading control. Data are mean ± SD ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; Student’s t-test). j Immunofluorescence staining of TKTL1, HIF-1α, and HK2 protein expression in HCC tissues. Nuclei: DAPI (blue). Scale bar: 150 µm

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Transketolase-like 1 potentiates PD-1 blockade in hepatocellular carcinoma by glycolysis to prime dendritic cell lactylation

    doi: 10.1038/s41392-026-02875-2

    Figure Lengend Snippet: TKTL1 reprograms glucose metabolism through glycolysis instead of the PPP to stabilize the HIF-1α/HK2/PD-L1 axis and drive anti-PD-1 sensitivity in HCC. a mRNA expression of glycolysis-related genes (SLC2A1, HK2, HKDC1) in TKTL1-knockdown Hep-3B cells, determined by RNA sequencing. b KEGG pathway enrichment analysis of downregulated differentially expressed genes (DEGs) in TKTL1-knockdown Hep-3B cells, highlighting Glycolysis/Gluconeogenesis and HIF-1α signaling pathways. c Bubble plot of KEGG pathway enrichment for downregulated metabolites from non-targeted metabolomics of TKTL1-knockdown cells, focusing on central carbon metabolism. d Integrative analysis of downregulated DEGs (RNA sequencing) and metabolites (non-targeted metabolomics), visualized as a ranked plot showing enrichment in glycolytic pathways. e Western blot analysis of glycolytic enzymes (GLUT1, HK2, PKM2, ENO1, LDHA) and TKTL1 in HCC-LM3 and Hep-3B cells with TKTL1 knockdown or overexpression. β-actin serves as a loading control. f 13 C-labeled glucose metabolic flux tracing analysis, showing the relative abundance of metabolites in glycolysis, PPP and tricarboxylic acid (TCA) cycle in TKTL1-knockdown vs. negative control (NC) cells. g Extracellular acidification rate (ECAR) measurements (left) and lactic acid production (right) in HCC-LM3 and Hep-3B cells under TKTL1 knockdown or overexpression. Data are mean ± SD ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; Student’s t-test). h , i Western blot analysis of TKTL1, HIF-1α, HK2, and PD-L1 protein expression in HCC-LM3 and Hep-3B cells with TKTL1 knockdown or overexpression. β-actin serves as a loading control. Data are mean ± SD ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; Student’s t-test). j Immunofluorescence staining of TKTL1, HIF-1α, and HK2 protein expression in HCC tissues. Nuclei: DAPI (blue). Scale bar: 150 µm

    Article Snippet: A combined secondary antibody was applied and left to incubate for 1 h. To maintain the integrity of the nucleus, DAPI staining (Beyotime, China) was utilized.

    Techniques: Sensitivity, Expressing, Knockdown, RNA Sequencing, Analysis, Protein-Protein interactions, Western Blot, Over Expression, Control, Labeling, Negative Control, Immunofluorescence, Staining

    TKTL1 activates glycolysis pathway by promoting HIF-1α deubiquitination through recruitment of USP9X in HCC. a Cycloheximide (CHX) chase assay in OE-VE (vector control) and OE-TKTL1 (TKTL1 overexpression) cells, assessing HIF-1α protein degradation kinetics over 0, 4, 8, and 12 h. β-actin serves as a loading control. b CHX chase assay in Sh-NC (negative control) and Sh-TKTL1 (TKTL1 knockdown) cells, evaluating HIF-1α degradation with or without proteasome inhibitor MG132 treatment. β-actin serves as a loading control. c Ubiquitination assay of HIF-1α in HCC-LM3 (Sh-NC vs. Sh-TKTL1) and Hep-3B (OE-VE vs. OE-TKTL1) cells treated with MG132. Immunoprecipitation (IP) with HIF-1α antibody and antibody incubation with ubiquitin (Ub) antibody detect ubiquitinated HIF-1α. d Co-immunoprecipitation (Co-IP) assay of endogenous proteins in HCC-LM3 and Hep-3B cells, confirming the interaction between TKTL1 and HIF-1α. IgG serves as a negative control; input lysates verify protein expression. e Co-IP assay of exogenous proteins in HEK-293T cells transfected with TKTL1 and HIF-1α expression plasmids, validating the TKTL1-HIF-1α interaction. IgG serves as a negative control. f Intersection analysis of TKTL1-interacting proteins identified via IP and deubiquitinating enzyme (DUB) family members, pinpointing USP9X as a key overlapping binding partner of TKTL1. g , h Co-IP assay identifying USP9X as a TKTL1-interacting protein. Co-IP assay demonstrating the interaction between USP9X and HIF-1α. IgG serves as a negative control. i GST-pull down assay transfected with Myc-USP9X, HA-TKTL1, and Flag-HIF-1α plasmids, verifying the formation of the TKTL1-USP9X-HIF-1α ternary complex. j AI-predicted structural model of the TKTL1-USP9X-HIF-1α ternary complex, illustrating the binding interface and spatial configuration of the three proteins. k IP assay using HIF-1α domain mutants in HEK-293T cells, confirming that USP9X binds to the inhibitory domain (ID) of HIF-1α. l IP assay using TKTL1 domain mutants in HEK-293T cells, identifying that HIF-1α binds to the T-pyr domain of TKTL1 and USP9X binds to the T-pyr domain of TKTL1. m Confocal laser scanning microscopy showing the cytoplasmic colocalization of TKTL1, HIF-1α, and USP9X in HCC-LM3 and Hep-3B cells. Nuclei are stained with DAPI (blue). n Immunofluorescence staining of HCC tissue microarrays showing the colocalization of TKTL1, HIF-1α, and USP9X. Inserted merge images confirm triprotein colocalization. Correlation analysis of TKTL1 and HIF-1α expression levels in HCC tissues (Pearson’s correlation coefficient: r = 0.1107, p = 0.003). Scale bar: 150 µm

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Transketolase-like 1 potentiates PD-1 blockade in hepatocellular carcinoma by glycolysis to prime dendritic cell lactylation

    doi: 10.1038/s41392-026-02875-2

    Figure Lengend Snippet: TKTL1 activates glycolysis pathway by promoting HIF-1α deubiquitination through recruitment of USP9X in HCC. a Cycloheximide (CHX) chase assay in OE-VE (vector control) and OE-TKTL1 (TKTL1 overexpression) cells, assessing HIF-1α protein degradation kinetics over 0, 4, 8, and 12 h. β-actin serves as a loading control. b CHX chase assay in Sh-NC (negative control) and Sh-TKTL1 (TKTL1 knockdown) cells, evaluating HIF-1α degradation with or without proteasome inhibitor MG132 treatment. β-actin serves as a loading control. c Ubiquitination assay of HIF-1α in HCC-LM3 (Sh-NC vs. Sh-TKTL1) and Hep-3B (OE-VE vs. OE-TKTL1) cells treated with MG132. Immunoprecipitation (IP) with HIF-1α antibody and antibody incubation with ubiquitin (Ub) antibody detect ubiquitinated HIF-1α. d Co-immunoprecipitation (Co-IP) assay of endogenous proteins in HCC-LM3 and Hep-3B cells, confirming the interaction between TKTL1 and HIF-1α. IgG serves as a negative control; input lysates verify protein expression. e Co-IP assay of exogenous proteins in HEK-293T cells transfected with TKTL1 and HIF-1α expression plasmids, validating the TKTL1-HIF-1α interaction. IgG serves as a negative control. f Intersection analysis of TKTL1-interacting proteins identified via IP and deubiquitinating enzyme (DUB) family members, pinpointing USP9X as a key overlapping binding partner of TKTL1. g , h Co-IP assay identifying USP9X as a TKTL1-interacting protein. Co-IP assay demonstrating the interaction between USP9X and HIF-1α. IgG serves as a negative control. i GST-pull down assay transfected with Myc-USP9X, HA-TKTL1, and Flag-HIF-1α plasmids, verifying the formation of the TKTL1-USP9X-HIF-1α ternary complex. j AI-predicted structural model of the TKTL1-USP9X-HIF-1α ternary complex, illustrating the binding interface and spatial configuration of the three proteins. k IP assay using HIF-1α domain mutants in HEK-293T cells, confirming that USP9X binds to the inhibitory domain (ID) of HIF-1α. l IP assay using TKTL1 domain mutants in HEK-293T cells, identifying that HIF-1α binds to the T-pyr domain of TKTL1 and USP9X binds to the T-pyr domain of TKTL1. m Confocal laser scanning microscopy showing the cytoplasmic colocalization of TKTL1, HIF-1α, and USP9X in HCC-LM3 and Hep-3B cells. Nuclei are stained with DAPI (blue). n Immunofluorescence staining of HCC tissue microarrays showing the colocalization of TKTL1, HIF-1α, and USP9X. Inserted merge images confirm triprotein colocalization. Correlation analysis of TKTL1 and HIF-1α expression levels in HCC tissues (Pearson’s correlation coefficient: r = 0.1107, p = 0.003). Scale bar: 150 µm

    Article Snippet: A combined secondary antibody was applied and left to incubate for 1 h. To maintain the integrity of the nucleus, DAPI staining (Beyotime, China) was utilized.

    Techniques: Plasmid Preparation, Control, Over Expression, Negative Control, Knockdown, Ubiquitin Proteomics, Immunoprecipitation, Incubation, Co-Immunoprecipitation Assay, Expressing, Transfection, Analysis, Binding Assay, GST Pulldown Assay, Confocal, Laser-Scanning Microscopy, Staining, Immunofluorescence, Tissue